GLUCOSE SENSOR EMPLOYING SEMICONDUCTOR NANOELECTRONIC DEVICE

• US 20110021894A1
• Filed: 09/30/2010
• Published: 01/27/2011
• Est. Priority Date: 04/01/2008
• Status: Abandoned Application

• Current Assignee: Trustees of Boston University
• Original Assignee: Trustees of Boston University
• Inventors: Mohanty, Pritiraj, Wang, Xihua, Chen, Yu, Erramilli, Shyamsunder
• Application Number:
  US12/894,792
• Publication Number:
  US 20110021894A1
• Time in Patent Office: Days
• US Class Current: 600/345
• CPC Class Codes: A61B 2562/0285 Nanoscale sensors
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/14865 invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
• CPC Class Codes: A61M 2205/3303 Using a biosensor
• CPC Class Codes: A61M 2230/201 Glucose concentration
• CPC Class Codes: A61M 5/1723 using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00
• CPC Class Codes: G01N 27/3272 Test elements therefor, i.e. disposable laminated substrates with electrodes, reagent and channels optical biosensors G01N33/52
• CPC Class Codes: G01N 33/54373 involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings

Abstract

A glucose sensor employs a programmable glucose sensor array of a relatively large number of nanoelectronic devices (e.g. semiconductor field-effect devices) having control surfaces functionalized with a glucose-reactive substance and generating sensing signals indicative of sensed glucose level of a bodily fluid. The devices are divided into sub-sets sequentially enabled over successive intervals to achieve overall sensor lifetime many times longer than the lifetime of any single device in operation.

Claims

1. A glucose sensor, comprising:

a nanoelectronic device having a control surface functionalized with a glucose-reactive substance; and

a fluid interface structure configured to allow contact between the control surface and a bodily fluid.

2. A glucose sensor according to claim 1, comprising an array of the nanoelectronic devices having respective control surfaces also functionalized with the glucose-reactive substance, and wherein the fluid interface structure is configured to allow contact between the control surfaces and the bodily fluid.

3. A glucose sensor according to claim 1, wherein the nanoelectronic device is configured such that chemical interaction between the glucose-reactive substance and glucose in the bodily fluid affects electrical conduction characteristics of the nanoelectronic device.

4. A glucose sensor according to claim 1, wherein the nanoelectronic device is configured such that chemical interaction between the glucose-reactive substance and glucose in the bodily fluid effects capacitive or other parametric changes of the nanoelectronic device.

5. A glucose sensor according to claim 1, wherein the nanoelectronic device has a sensing element critical dimension less than 100 nm.

6. A glucose sensor according to claim 1, wherein the nanoelectronic device has a sensing element critical dimension less than 500 nm.

14. A system for controlling blood glucose level by selective administration of insulin to a subject, comprising:

the glucose sensor of claim 1 having the control surface in intimate contact with the bodily fluid of a subject;

an insulin pump configured to administer insulin to the subject as a function of pump control signals supplied to the insulin pump; and

a control unit coupled to receive a sensing output signal from the glucose sensor and to perform a control algorithm to (1) ascertain an amount of insulin to be supplied to the subject based on sensed glucose levels as conveyed by the sensing output signal, and (2) generate the pump control signals to cause the insulin pump to dispense the ascertained amount of insulin.

15. A system according to claim 14 wherein the glucose sensor is implanted into a body tissue of the subject.

7. A glucose sensor, comprising:

an array of nanoelectronic devices having respective control surfaces functionalized with a glucose-reactive substance which chemically interacts with glucose to affect electrical conduction characteristics of the nanoelectronic devices, the array being configured to allow for intimate contact between the control surfaces and a glucose-carrying bodily fluid, the array of nanoelectronic devices being logically organized into a plurality of individually operable subsets of the nanoelectronic devices, each subset being operable for only a limited period before operational degradation due to interaction between the bodily fluid and operating nanoelectronic sensors of the subset;

device selection circuitry operative in response to control inputs to enable electrical sensing operation of a selected one of the subsets of the nanoelectronic devices to generate respective sensing output signals while simultaneously disabling such electrical sensing operation of remaining ones of the subsets of the nanoelectronic devices; and

control circuitry operative to generate the control signals so as to serially enable electrical operation of successive ones of the subsets of the nanoelectronic devices over an extended period generally equal to the product of the limited period and the number of the subsets of the nanoelectronic devices.

8. A glucose sensor according to claim 7 wherein the array is configured for implantation into a body tissue to provide for the intimate contact between the control surfaces and the glucose-carrying bodily fluid.

9. A glucose sensor according to claim 7 wherein the nanoelectronic sensors are nanoscale field-effect devices.

10. A glucose sensor according to claim 7 wherein the control circuitry is further operative to effect sampled operation of the nanoelectronic devices of the selected subset to achieve reduced power consumption compared to continuous operation of the nanoelectronic devices.

11. A glucose sensor according to claim 7 wherein the control circuitry is further operative to engage in performance monitoring of the nanoelectronic devices to ascertain how accurately the sensing output signals reflect an actual glucose level of the glucose-carrying bodily fluid.

12. A glucose sensor according to claim 11 wherein the performance monitoring is utilized to switch to a new subset when a current subset shows sufficient operational degradation to signal the need for a switch.

13. A glucose sensor according to claim 11 wherein predetermined ones of the nanoelectronic devices are operated as control devices whose outputs are utilized in the performance monitoring of the control circuitry.

16. A method of continual, extended sensing of glucose level of a glucose-carrying bodily fluid, comprising:

bringing the glucose-carrying bodily fluid into intimate contact with control surfaces of an array of nanoelectronic devices of a glucose sensor, the control surfaces being functionalized with a glucose-reactive substance which chemically interacts with glucose to affect electrical conduction characteristics of the nanoelectronic devices, the array of nanoelectronic devices being logically organized into a plurality of individually operable subsets of the nanoelectronic devices, each subset being operable for only a limited period before operational degradation due to interaction between the bodily fluid and operating nanoelectronic sensors of the subset;

in response to control inputs, enabling electrical sensing operation of a selected one of the subsets of the nanoelectronic devices to generate respective sensing output signals while simultaneously disabling such electrical sensing operation of remaining ones of the subsets of the nanoelectronic devices; and

generating the control inputs to serially enable electrical operation of successive ones of the subsets of the nanoelectronic devices over an extended period generally equal to the product of the limited period and the number of the subsets of the nanoelectronic devices.

17. A method according to claim 16 further comprising operating the nanoelectronic devices of the selected subset in a sampled manner to achieve reduced power consumption compared to continuous operation of the nanoelectronic devices of the selected subset.

18. A method according to claim 16 further comprising engaging in performance monitoring of the nanoelectronic devices to ascertain how accurately the sensing output signals reflect an actual glucose level of the glucose-carrying bodily fluid.

19. A method according to claim 18 wherein the performance monitoring is utilized to switch to a new subset when a current subset shows sufficient operational degradation to signal the need for a switch.

20. A method according to claim 18 wherein predetermined ones of the nanoelectronic devices are operated as control devices whose outputs are utilized in the performance monitoring of the control circuitry.